INmune Bio, Inc.
INMBNASDAQHealthcare● Active
$1.24
$-0.02(-1.59%)
Market Cap$32965720
P/E Ratio—
52W High$11.64
52W Low$1.09
INmune Bio, Inc. (INMB) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · INMB · as of 2026-06-09
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $0.05M | $0.01M | $0.15M | $0.37M | $0.18M |
| Cost of Revenue | $0.00M | $0.00M | $0.00M | $0.00M | $0.00M |
| Gross Profit | $0.05M | $0.01M | $0.15M | $0.37M | $0.18M |
| Gross Margin %(computed) | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
| Operating Expenses | |||||
| R&D Expenses | $20.66M | $33.17M | $20.27M | $17.07M | $20.54M |
| G&A Expenses | $10.26M | $9.48M | $9.62M | $9.26M | $8.79M |
| Total Operating Expenses | $30.92M | $42.65M | $29.90M | $26.32M | $29.33M |
| Operating Income | ($30.87M) | ($42.63M) | ($29.74M) | ($25.95M) | ($29.15M) |
| Operating Margin %(computed) | — | — | — | — | — |
| Interest Income | $0.85M | $0.00M | $0.00M | $0.00M | $0.00M |
| Interest Expense | $0.00M | $0.00M | $0.00M | $0.00M | $0.00M |
| Income Before Tax | ($45.93M) | ($42.08M) | ($30.01M) | ($27.30M) | ($30.34M) |
| Income Tax Expense | $0.00M | $0.00M | $0.00M | $0.00M | $0.00M |
| Net Income | ($45.93M) | ($42.08M) | ($30.01M) | ($27.30M) | ($30.34M) |
| Net Margin %(computed) | — | — | — | — | — |
| Per Share & EBITDA | |||||
| EPS (Basic) | $-1.86 | $-2.11 | $-1.67 | $-1.52 | $-1.88 |
| Wtd Avg Shares | 26.59M | 19.94M | 17.98M | 17.93M | 16.13M |
| EBITDA | ($30.79M) | ($42.08M) | $0.00M | $0.00M | $0.00M |
| EBITDA Margin %(computed) | — | — | 0.00% | 0.00% | 0.00% |
Data source: Financial Modeling Prep · Last updated: 2026-06-09 · USD · M
Explore more INmune Bio, Inc. data
About INmune Bio, Inc. (INMB) Income Statement
INmune Bio, Inc. (INMB) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2025, INMB reported revenue of $0.00B, gross profit of $0.00B (gross margin 100.00%), and net income of ($0.05B) — a net profit margin of -91866.00%.
Frequently asked questions
INMB · 4 questionsINmune Bio, Inc. (INMB) reported revenue of $0.00B for 2025, up 257.1% year-over-year.
INMB revenueINMB salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-09